Curis reveals plans to combat cancer with 'Smac' contender in PhI; Dealmakers: Watch out for pharma 'DPOs' and 'NINAs';

@FierceBiotech: From FierceCRO.com: Icon ticks up guidance as revenue leaps another 21%. Item | Follow @FierceBiotech

@RyanMFierce: Lots of CHMP news today, notable win for Novartis in COPD and loss for Pfizer in RA. More | Follow @RyanMFierce

@EmilyMFierce: Antibody effective at fighting norovirus in chimps. Story | Follow @EmilyMFierce

> Curis ($CRIS) has launched a Phase I study for CUDC-427, a Smac mimetic, against solid tumors and lymphoma. Release

> Adaptimmune has announced a Phase I/IIa study of a personalized T cell therapy for cancer. Release

> Should we worry? A CNBC commentator invoked last year's fascination with IPOs for cloud computing companies in a piece about the "hot" biotech sector. Item

Medical Device News

@FierceMedDev: If you missed it earlier this week, check out the "Top 10 Med Tech Investments of Q2" special report on FierceMedDev: Feature | Follow @FierceMedDev

@MarkHFierce: A blood diagnostic to predict sepsis death may be within reach. More | Follow @MarkHFierce

@DamianFierce: Cepheid wins FDA nod for combo TB test. Article | Follow @DamianFierce

 @MichaelGFierce: Silk brain implant releases seizure-reducing epilepsy drugs. Story | Follow @MichaelGFierce

> MC10, Reebok launch brain-impact sensor. News

> Edwards' Sapien valve drives a heady second quarter. Report

> Brain implant made from silk stems epileptic seizures. Item

Pharma News

@FiercePharma: Still trending: Our special report on the Top 20 Orphan Drugs by 2018. Report | Follow @FiercePharma

@EricPFierce:  CEO Bob Hugin keeps pushing drumaker to new heights. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: GlaxoSmithKline replaces head of business in China amid bribery investigation. Article | Follow @CarlyHFierce

> Gilead earnings firm, but company gets shot in arm from Vertex setback. Item

> Humira stays strong for AbbVie as drugmaker scrambles for new offerings. Article

> EMA finds GLP-1 diabetes drugs safe to use. Report

And Finally… Atlas Venture Partner Bruce Booth offers some tips about the various types of dealmakers (and deal destroyers) in pharma. What's a deal NINA? Think the opposite of ninja. Blog

Suggested Articles

The deal is worth $50 million upfront but could balloon in value to more than $2 billion if all the milestones are hit.  

The same week Bayer said it was putting $4 billion on the table for gene therapy biotech AskBio, the German pharma has nabbed a Roche exec.

Novartis is spending $69 million upfront on a pair of experimental drugs from Fierce 15 winner Molecular Partners.